Related Experiment Video
Updated: Dec 27, 2025

Oligopeptide Competition Assay for Phosphorylation Site Determination
Published on: May 18, 2017
Regulation of NRF2 by Na+/K+-ATPase: implication of tyrosine phosphorylation of Src
1College of Pharmacy and Integrated Research Institute for Drug Development, Dongguk University, Goyang, Korea.
Abstract:
Tumors adapt well to the imbalanced redox status created by rapid growth and limited nutrient availability because they highly express high levels of NRF2 to counteract oxidative stress. Therefore, inhibition of NRF2 is currently considered a feasible strategy for development of chemotherapeutic agents. In the present study, we identified that Na+/K+-ATPase regulates NRF2 in A549 cells. Suppression of Na+/K+-ATPase by convallatoxin or siRNAs downregulates NRF2 in A549 cells, and this event is mediated by Ca2+-dependent induction of CSK1 and subsequent phosphorylation of SRC at Tyr 527. Consistent with this finding, knocking down the α1 or β1 subunit of Na+/K+-ATPase promotes the generation of intracellular ROS by cisplatin and potentiates cisplatin-induced apoptosis and autophagy in A549 cells. Our study reveals that the signaling axis composed of Na+/K+-ATPase, CSK1, and tyrosine phosphorylation of Src could be a useful target for development of NRF2 inhibitors.
Insights
This study reveals that inhibiting Na+/K+-ATPase downregulates NRF2, a key protein in cancer cell adaptation. This pathway, involving Ca2+, CSK1, and Src, offers a new target for NRF2 inhibitor development in cancer therapy.
Area of Science:
- Biochemistry
- Cell Biology
- Oncology
Background:
- Tumors utilize high NRF2 levels to manage oxidative stress, making NRF2 inhibition a promising chemotherapeutic strategy.
- Na+/K+-ATPase activity is crucial for cellular homeostasis and has been implicated in various diseases.
Purpose of the Study:
- To investigate the regulatory role of Na+/K+-ATPase in NRF2 expression in A549 lung cancer cells.
- To identify the molecular mechanisms linking Na+/K+-ATPase activity to NRF2 regulation.
- To explore the potential of targeting the Na+/K+-ATPase-CSK1-Src axis for NRF2-targeted cancer therapy.
Main Methods:
- Utilized convallatoxin and siRNAs to suppress Na+/K+-ATPase function in A549 cells.
- Assessed NRF2 levels, intracellular reactive oxygen species (ROS) generation, and cisplatin-induced apoptosis and autophagy.
- Investigated the involvement of Ca2+, CSK1, and Src phosphorylation in the regulatory pathway.
Main Results:
- Suppression of Na+/K+-ATPase led to NRF2 downregulation in A549 cells.
- This effect was mediated by Ca2+-dependent induction of CSK1 and subsequent Src phosphorylation at Tyr 527.
- Knocking down Na+/K+-ATPase subunits enhanced cisplatin-induced ROS production, apoptosis, and autophagy.
Conclusions:
- Na+/K+-ATPase plays a significant role in regulating NRF2 expression in lung cancer cells.
- The identified signaling axis (Na+/K+-ATPase-CSK1-Src) represents a novel therapeutic target for developing NRF2 inhibitors.
- Targeting this pathway could potentiate the efficacy of chemotherapeutic agents like cisplatin.
Related Concept Videos
Regulation of Nuclear Protein Sorting
Receptor Tyrosine Kinases
MAPK Signaling Cascades
PI3K/mTOR/AKT Signaling Pathway
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...

